156 related articles for article (PubMed ID: 32916470)
41. Properties of L-type amino acid transporter 1 in epidermal ovarian cancer.
Kaji M; Kabir-Salmani M; Anzai N; Jin CJ; Akimoto Y; Horita A; Sakamoto A; Kanai Y; Sakurai H; Iwashita M
Int J Gynecol Cancer; 2010 Apr; 20(3):329-36. PubMed ID: 20375792
[TBL] [Abstract][Full Text] [Related]
42. Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy.
Li L; Di X; Wu M; Sun Z; Zhong L; Wang Y; Fu Q; Kan Q; Sun J; He Z
Nanomedicine; 2017 Apr; 13(3):987-998. PubMed ID: 27890657
[TBL] [Abstract][Full Text] [Related]
43. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
44. Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1).
Chien HC; Colas C; Finke K; Springer S; Stoner L; Zur AA; Venteicher B; Campbell J; Hall C; Flint A; Augustyn E; Hernandez C; Heeren N; Hansen L; Anthony A; Bauer J; Fotiadis D; Schlessinger A; Giacomini KM; Thomas AA
J Med Chem; 2018 Aug; 61(16):7358-7373. PubMed ID: 30048132
[TBL] [Abstract][Full Text] [Related]
45. 2-[
Verhoeven J; Baguet T; Piron S; Pauwelyn G; Bouckaert C; Descamps B; Raedt R; Vanhove C; De Vos F; Goethals I
Nucl Med Biol; 2020; 82-83():9-16. PubMed ID: 31841816
[TBL] [Abstract][Full Text] [Related]
46. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
[TBL] [Abstract][Full Text] [Related]
47. [Drug Discovery Targeting an Amino Acid Transporter for Diagnosis and Therapy].
Wiriyasermkul P; Moriyama S; Kongpracha P; Nagamori S
Yakugaku Zasshi; 2021; 141(4):501-510. PubMed ID: 33790117
[TBL] [Abstract][Full Text] [Related]
48. Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
Kobayashi K; Ohnishi A; Promsuk J; Shimizu S; Kanai Y; Shiokawa Y; Nagane M
Neurosurgery; 2008 Feb; 62(2):493-503; discussion 503-4. PubMed ID: 18382329
[TBL] [Abstract][Full Text] [Related]
49. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.
Cai L; Kirchleitner SV; Zhao D; Li M; Tonn JC; Glass R; Kälin RE
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963507
[TBL] [Abstract][Full Text] [Related]
50. Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy.
Ogawa K; Mizuno Y; Washiyama K; Shiba K; Takahashi N; Kozaka T; Watanabe S; Shinohara A; Odani A
Nucl Med Biol; 2015 Nov; 42(11):875-9. PubMed ID: 26235266
[TBL] [Abstract][Full Text] [Related]
51. Role of l-Type Amino Acid Transporter 1 at the Inner Blood-Retinal Barrier in the Blood-to-Retina Transport of Gabapentin.
Akanuma SI; Yamakoshi A; Sugouchi T; Kubo Y; Hartz AMS; Bauer B; Hosoya KI
Mol Pharm; 2018 Jun; 15(6):2327-2337. PubMed ID: 29688723
[TBL] [Abstract][Full Text] [Related]
52. Diagnosis of bladder cancer using
Mahendra I; Hanaoka H; Yamaguchi A; Amartuvshin T; Tsushima Y
Ann Nucl Med; 2020 May; 34(5):329-336. PubMed ID: 32144655
[TBL] [Abstract][Full Text] [Related]
53. L-Type amino acid transporter 1 as a target for drug delivery.
Puris E; Gynther M; Auriola S; Huttunen KM
Pharm Res; 2020 May; 37(5):88. PubMed ID: 32377929
[TBL] [Abstract][Full Text] [Related]
54. Selective Inhibition of L-type Amino Acid Transporter 1 Suppresses Cell Proliferation in Ovarian Clear Cell Carcinoma.
Sekine M; Koh I; Nakamoto K; Nosaka S; Tomono K; Sugimoto J; Kudo Y
Anticancer Res; 2023 Jun; 43(6):2509-2517. PubMed ID: 37247931
[TBL] [Abstract][Full Text] [Related]
55. Tyrosine-Chlorambucil Conjugates Facilitate Cellular Uptake through L-Type Amino Acid Transporter 1 (LAT1) in Human Breast Cancer Cell Line MCF-7.
Pocasap P; Weerapreeyakul N; Timonen J; Järvinen J; Leppänen J; Kärkkäinen J; Rautio J
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32244913
[TBL] [Abstract][Full Text] [Related]
56. Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells.
Kim DK; Kanai Y; Choi HW; Tangtrongsup S; Chairoungdua A; Babu E; Tachampa K; Anzai N; Iribe Y; Endou H
Biochim Biophys Acta; 2002 Sep; 1565(1):112-21. PubMed ID: 12225859
[TBL] [Abstract][Full Text] [Related]
57. A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells.
Huttunen KM; Gynther M; Huttunen J; Puris E; Spicer JA; Denny WA
J Med Chem; 2016 Jun; 59(12):5740-51. PubMed ID: 27253989
[TBL] [Abstract][Full Text] [Related]
58. Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging.
Wei L; Tominaga H; Ohgaki R; Wiriyasermkul P; Hagiwara K; Okuda S; Kaira K; Oriuchi N; Nagamori S; Kanai Y
Cancer Sci; 2016 Mar; 107(3):347-52. PubMed ID: 26749017
[TBL] [Abstract][Full Text] [Related]
59. Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors.
Wu W; Dong Y; Gao J; Gong M; Zhang X; Kong W; Li Y; Zeng Y; Si D; Wei Z; Ci X; Jiang L; Li W; Li Q; Yi X; Liu C
Cancer Sci; 2015 Jun; 106(6):747-756. PubMed ID: 25867020
[TBL] [Abstract][Full Text] [Related]
60. L-Citrulline Level and Transporter Activity Are Altered in Experimental Models of Amyotrophic Lateral Sclerosis.
Gyawali A; Gautam S; Hyeon SJ; Ryu H; Kang YS
Mol Neurobiol; 2021 Feb; 58(2):647-657. PubMed ID: 33000451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
